Research information only. PrecisePep is an educational library. It is not medical advice and is not intended to assist, encourage or enable self-administration. The compounds documented here are research chemicals — most are not approved for human use. Read the full disclaimer.
PrecisePep/Peptide Library/Liraglutide
Metabolic & Adipose Regulation
Victoza® · Saxenda® · NN2211
The daily GLP-1 agonist that proved the class could reduce cardiovascular death — now superseded on potency, and still the agent with the most randomised evidence in PCOS.
Liraglutide is the drug that made this class cardiovascular medicine. LEADER, published in 2016, randomised over 9,000 people with type 2 diabetes at high cardiovascular risk and reported a reduction in major adverse cardiovascular events and in cardiovascular death.[1] That result changed how the whole class was understood — from glucose-lowering agents to drugs with outcome benefit.
It is approved as Victoza for type 2 diabetes and, at a higher dose, as Saxenda for chronic weight management. HbA1c reduction is solid but below semaglutide and well below tirzepatide, and weight loss is roughly half what the newer weekly agents deliver.[2]
Two things keep it relevant. It is daily rather than weekly, with a ~13-hour half-life — so if it is not tolerated, the exposure clears in a day or two rather than a month. And it carries the most randomised evidence in PCOS of any agent in the class, which matters given how often GLP-1 agonists are discussed for that condition on the basis of "class evidence" that is largely liraglutide's.
A weekly agent that causes intolerable nausea keeps causing it for weeks. A daily agent with a 13-hour half-life can be reduced or stopped and the effect is gone within days. For anyone who has had a bad time on a weekly drug, that is a genuine and under-discussed reason to consider a daily one.
GLP-1 receptor agonism. Glucose-dependent amplification of insulin secretion, suppression of inappropriate glucagon release, slowed gastric emptying, and central appetite suppression through hypothalamic and hindbrain circuits — the standard class mechanism.
Acylation for a daily half-life. A C16 fatty-acid chain confers albumin binding, extending half-life from GLP-1's few minutes to about thirteen hours. Semaglutide's later modifications extended this to a week; liraglutide sits between native GLP-1 and the weekly agents.
Cardiovascular effects beyond glucose. The LEADER benefit emerged in a pattern suggesting mechanisms beyond glycaemic improvement alone — proposed to include anti-inflammatory and endothelial effects, as for the rest of the class.
Glucose-dependence. Insulinotropic action requires elevated glucose, so monotherapy carries low intrinsic hypoglycaemia risk — a property that disappears alongside insulin or sulfonylureas.
Effects that have been reported. A study-tier entry means a result was published — not that the effect is established, reproducible, or transferable from a rodent to a person.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Randomised trial in over 9,000 adults with type 2 diabetes at high cardiovascular risk, reporting reduced major adverse cardiovascular events and cardiovascular mortality. The trial that established outcome benefit for the class.
Consistent glycaemic improvement across the LEAD programme, with efficacy below semaglutide and tirzepatide in head-to-head comparison but well established in its own right.
The SCALE programme supported approval as Saxenda for chronic weight management, with mean reductions around 8% — roughly half what the newer weekly agents achieve.
Liraglutide has more randomised data in PCOS than any other GLP-1 receptor agonist, reporting improved insulin sensitivity, reduced androgens, weight loss and improved menstrual regularity. When other pages cite "class evidence" in PCOS, this is a large part of what they are citing.
A ~13-hour half-life means dose reduction or discontinuation clears the effect within days. Clinically useful and a genuine advantage over weekly agents for tolerability management.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Liraglutide has been studied in Alzheimer disease with mixed results. The class hypothesis is mechanistically motivated by CNS GLP-1 receptor expression; check current readouts before treating as established.
The daily half-life argument, extended to anyone who has failed a weekly agent on adverse effects rather than efficacy. Reasonable clinical logic; not a trial finding.
From the class addiction literature, strongest for semaglutide. Extrapolation to liraglutide is plausible and less directly evidenced.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Consistently reported — less appetite suppression, less weight loss, and correspondingly milder gastrointestinal effects. Which is what the comparative trial data would predict.
The dominant reason people move off it, more often than efficacy.
Users who reduce the dose report the effect settling within a day or two rather than a fortnight.
Weekly agents dominate the research-chemical market. Liraglutide appears occasionally and is generally sought by people who have specifically failed a weekly drug.
Adverse effects, contraindications and unknowns. The grey-market tier is where under-reporting is worst: uncontrolled use produces no systematic safety surveillance at all, so absence of a reported harm is not evidence of safety.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Nausea, vomiting, diarrhoea and constipation — the dominant category, dose-dependent, concentrated during titration.
From rodent findings. Contraindicated in personal or family history of medullary thyroid carcinoma or MEN2.
Labelled warnings across the class, with gallbladder events following the rapid-weight-loss association.
Glucose-dependence limits intrinsic risk, but that protection does not extend to concurrent insulin or sulfonylurea therapy — dose reduction of those agents is standard practice on initiation.
A recognised class concern relevant to any planned procedure requiring sedation.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Well characterised across the class. Benefit is contingent on continuation.
Improving insulin sensitivity and losing weight restores ovulation in a substantial proportion. This class is contraindicated in pregnancy and requires discontinuation beforehand.
Delayed gastric emptying alters absorption of a narrow-therapeutic-index, fasting-dependent drug. Less pronounced than with the weekly agents but the mechanism is the same.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The main early complaint, generally settling and easier to manage than on weekly agents.
More frequently reported than with weekly agents, unsurprisingly given seven times the injection frequency.
The characteristic longer-run class complaints.
Figures below are documented, not recommended. Study ranges come from published protocols in the stated model; grey-market ranges are what the research community reports using and carry no safety validation of any kind.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
0.6 mg daily for at least one week — explicitly a tolerability dose, not a therapeutic one — then 1.2 mg, with escalation to 1.8 mg if further glycaemic control is needed.
Weekly 0.6 mg increments from 0.6 to 3.0 mg for chronic weight management.
| Product | Titration | Maintenance | Indication |
|---|---|---|---|
| Victoza | 0.6 mg ≥1 week | 1.2 or 1.8 mg daily | Type 2 diabetes |
| Saxenda | 0.6 mg weekly increments | 3.0 mg daily | Chronic weight management |
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Adverse events are dose-ordered while appetite suppression saturates earlier than maximal effect — the argument that applies across the class.
The daily half-life means a bad reaction is a short problem rather than a long one.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The common community range, frequently held at the lower labelled doses.
For those pursuing the weight indication.
Reported by people who could not tolerate semaglutide or tirzepatide, on the grounds that a shorter half-life is more forgiving.
Combination effects. Almost no peptide combination has been studied as a combination in humans; stack logic is overwhelmingly mechanistic inference and community practice. Each linked compound has its own page.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
The LEAD programme studied liraglutide alongside metformin, sulfonylureas and thiazolidinediones — the combination evidence here is genuine clinical trial data rather than inference.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Agonism at the same receptor with additive adverse effects and no additional mechanism.
Requires dose reduction of the concurrent agent. This is standard clinical practice and the most likely route to harm if ignored.
Delayed gastric emptying alters absorption kinetics of concomitant oral medication.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The standard clinical pairing, and common in community use too.
Whole schedules — dosing, titration, cycle length, and off-time — as documented in trials, as proposed from mechanism, and as circulated in the research community. Reproduced for study and comparison only.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
The endpoint the drug is titrated against clinically. Self-managing diabetes without it is managing an invisible variable.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The general community pattern.
Liraglutide is the odd compound in this section: for two of these three conditions it is not off-label interest at all, it is the approved indication with two decades of trial data behind it. The third — PCOS — is off-label, and is also where this molecule has more randomised evidence than any other GLP-1 agonist.
Approved does not mean self-administered. Victoza and Saxenda are prescription products with a boxed warning for thyroid C-cell tumours, a contraindication in personal or family history of medullary thyroid carcinoma or MEN 2, and a documented pancreatitis signal. The material below describes what the trials found and what the community discusses; it is not a route to obtaining or using the drug outside medical care.
Pathophysiology
Nicotine dependence is maintained by mesolimbic dopamine signalling. Quitting also produces an average weight gain of several kilograms, and fear of that gain is a measured barrier to attempting cessation and a measured cause of relapse.
Mechanistic rationale
The randomised evidence in this class is two small trials. Dulaglutide alongside varenicline did not improve abstinence — 63% against 65% — but prevented post-cessation weight gain, −4.6 kg against +0.5 kg. Exenatide alongside a nicotine patch did improve abstinence, 46.3% against 26.8%. Semaglutide has a large observational signal whose own investigators said it does not justify off-label use. Nothing has been tested for this agent, and in every trial the GLP-1 was added to a treatment that already works rather than replacing it.
Community reports
The consistent finding across the randomised literature is the weight, not the quitting. Post-cessation weight gain is real, specific and worth addressing; improved abstinence is not established, and the whole randomised evidence base is roughly 410 participants.
Components carrying the argument: GLP-1 receptor — class inference only
Pathophysiology
Type 2 diabetes is a progressive disorder of insulin resistance plus beta-cell failure. Glucose control alone does not reliably reduce cardiovascular death; the reason this class changed practice is that it does.
Mechanistic rationale
Liraglutide is glucose-dependent in its insulinotropic action, which is why it lowers HbA1c without the hypoglycaemia risk of sulphonylureas or insulin — unless it is combined with them. The LEAD programme established the glycaemic effect; LEADER (9,340 participants with type 2 diabetes at high cardiovascular risk) established a reduction in major adverse cardiovascular events and in cardiovascular death versus placebo. That result, not the HbA1c number, is why it sits high in the treatment algorithms.
Community reports
The daily schedule is the recurring complaint and the recurring advantage. People who could not tolerate weekly semaglutide sometimes report that liraglutide is manageable, because a missed or reduced daily dose self-corrects within a day rather than sitting in the system for a week.
Components carrying the argument: GLP-1 receptor — glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay
Pathophysiology
Insulin resistance drives hyperinsulinaemia; hyperinsulinaemia drives ovarian androgen production and suppresses SHBG, which raises free testosterone. Weight loss and improved insulin sensitivity unwind that loop from both ends.
Mechanistic rationale
More randomised PCOS data exists for liraglutide than for any other agent in this class, largely because it has been available longest. Trials — mostly small, mostly 12 to 32 weeks — have reported weight and waist reduction, improved insulin sensitivity, and in several, restored menstrual regularity, with combination against metformin studied more than either alone. The evidence is real; it is also thin next to the diabetes and obesity literature, and none of it is powered for pregnancy or live-birth outcomes.
Community reports
Community reporting concentrates on cycle regularity returning within a few months and on the emotional weight of that after years of irregularity. Reporting is self-selected — people for whom nothing changed rarely post.
Components carrying the argument: Weight loss plus a direct improvement in insulin sensitivity
Pathophysiology
Anovulation in PCOS is frequently reversible. When ovulation resumes, so does the possibility of conception — often without warning, in people who had stopped using contraception because they believed they could not conceive.
Mechanistic rationale
This class is contraindicated in pregnancy and the labelling asks for discontinuation in advance of a planned pregnancy. Liraglutide clears faster than the weekly agents, which shortens the washout, but the point stands: the treatment that restores fertility is the treatment that must stop before that fertility is used.
Community reports
Unplanned conception on incretins is a recurring theme in PCOS communities, frequently framed as a happy surprise. The clinical framing is less relaxed.
Components carrying the argument: A predictable consequence, not a side effect
Pathophysiology
Obesity is defended physiologically: energy restriction lowers the metabolic rate and raises hunger signalling, which is why most weight loss reverses.
Mechanistic rationale
The obesity indication uses 3.0 mg daily; the diabetes indication tops out at 1.8 mg. Same molecule, different product, different titration schedule, different label. The SCALE programme supported the obesity approval. Newer weekly agents produce substantially more weight loss, which is why liraglutide has largely been displaced for this use — not because it stopped working.
Community reports
People who have moved from liraglutide to a weekly agent almost universally report more weight loss; a minority report they preferred the daily version for tolerability and went back.
Components carrying the argument: Appetite and satiety signalling in the hypothalamus
| Question | Position |
|---|---|
| Approved for type 2 diabetes? | Yes — Victoza, up to 1.8 mg daily |
| Approved for obesity? | Yes — Saxenda, 3.0 mg daily |
| Approved for PCOS? | No — off-label, but the best-studied agent in the class |
| Cardiovascular outcome data | LEADER — MACE and cardiovascular death reduced |
| Boxed warning | Thyroid C-cell tumours (rodent); contraindicated in MTC / MEN 2 |
| Pregnancy | Contraindicated — discontinue in advance |
| Hypoglycaemia risk alone | Low — rises sharply with insulin or a sulphonylurea |
| Versus weekly agents | Less weight loss; easier to titrate and to stop |
Type 2 diabetes has an established treatment algorithm and it does not start here. Metformin remains first-line and is inexpensive; SGLT2 inhibitors have their own cardiovascular and renal outcome data; this class is added for people with established cardiovascular disease, chronic kidney disease, or when weight is central to the picture. Structured education, sleep, resistance training and dietary change are not the polite preamble to drug therapy — they change the trajectory of the disease and they compound with everything above.
For PCOS: metformin for the metabolic phenotype, combined hormonal contraceptives for hyperandrogenism and cycle control, letrozole first-line for ovulation induction, inositol with reasonable evidence and a benign safety profile. A 5–10% weight reduction alone restores ovulation in a meaningful proportion of people.
Physical-chemistry reference for laboratory handling of the lyophilised material. Reproduced so that stability and concentration mathematics can be studied — see the calculator for the arithmetic and the reconstitution guide for sterile technique.
The licensed product ships as a ready-to-use multi-dose pen requiring no reconstitution. Research-grade liraglutide is supplied lyophilised, commonly 5 or 10 mg per vial. At 1.2 mg daily a 10 mg vial is about eight days — far shorter than the weekly agents, which changes the in-use calculus.
Licensed: refrigerated 2–8 °C before first use, then room temperature for a defined in-use period. Research material lyophilised: −20 °C. Reconstituted: 2–8 °C.
Licensed: pre-filled pens. Research supply: commonly 5 mg and 10 mg.
Daily dosing means a vial is consumed quickly, which sidesteps the long in-use problem that affects the weekly compounds.
Regulatory status changes and differs by country. This is a summary for orientation, not legal advice — check your own jurisdiction.
Generic liraglutide is available for both indications. A generic of Victoza was approved in December 2024 for glycaemic control in type 2 diabetes, and Teva subsequently launched a generic of Saxenda for weight management in adults and adolescents aged 12 to 17. Liraglutide is the first GLP-1 receptor agonist to have generic equivalents for both diabetes and obesity.
That matters more than the efficacy comparison with the newer agents. The research-chemical market for incretins exists largely because licensed products are expensive; a generic, approved, pharmacy-supplied GLP-1 with two decades of safety data undercuts that argument directly — at a smaller weight effect than semaglutide or tirzepatide, and with a known one.
Approved. Licensed as Victoza for type 2 diabetes and Saxenda for chronic weight management, with equivalent approvals across the EU and UK. Prescription medicine with a boxed warning. Generic liraglutide has begun to appear following patent expiry in several markets, which changes the cost argument that drives much grey-market use of this class.
Regulatory and trial claims re-checked against primary sources on 16 August 2026. Checked: generics approved for both indications; Teva generic Saxenda launch. Approvals, trial readouts and compounding decisions move faster than anything else on this page — a date here means someone looked, not that nothing has changed since.
Metabolic modulators and peptide hormones are addressed under the WADA Prohibited List. Verify against the current list rather than assuming an approved medicine is permitted.
Links resolve to PubMed records, trial registries, publisher pages or primary documents. Where a body of work rather than a single paper is cited, the link opens a PubMed query so the full result set — including newer papers than this page — can be reviewed. Verify every claim against the primary source before relying on it.
For educational and research reference only. Nothing on this site is medical advice, a recommendation, or an instruction to administer any substance to a human being. Every figure on this page is a record of what has been reported, not a recommendation. Full disclaimer.
